AI drug design races ahead while clinical trials become the bottleneck
MaxUnfried · x · 2026-11-22
furstfly argues AI's biggest impact is in drug design, shifting the bottleneck to labs and clinical trials: by the time one drug finishes Phase 1, a next candidate could be 50% better — and doubled efficacy needs roughly 4x fewer patients, speeding enrollment and early stops. Reposter adds many FDA complaints excuse weak therapies.
More from AGI Musings
- 'There's never been a better time to go into math' amid AI boom — burny_tech · 2026-11-22
- Why the AI-anxious can see their roles dying but not what comes next — RileyRalmuto · 2026-11-22
- We are the ones inside the Chinese room, argues dev as AI hands out proofs — sytelus · 2026-11-22
- "Marx predicted generative AI": the labor theory of value debate goes viral — felpix_ · 2026-11-22
- Peter Wildeford puts 15-30% odds on AI proving the Riemann Hypothesis by 2035 — peterwildeford · 2026-11-22
- Maybe math was always trivial like chess, not hard like laundry — QuintinPope5 · 2026-11-22